/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Evogene Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.09 0.0047(0.47%) EVGN at 04 Dec 2025 04:31 PM Biotechnology
Lowest Today 1.04
Highest Today 1.075
Today’s Open 1.07
Prev. Close 1.055
52 Week High 2.42
52 Week Low 0.95
Day’s Range: Low 1.04 High 1.075
52-Week Range: Low 0.95 High 2.42
1 day return -
1 Week return -
1 month return -13.93
3 month return -13.93
6 month return -4.54
1 year return -27.08
3 year return +66.61
5 year return -73.14
10 year return -

Institutional Holdings

Virtu Financial LLC 0.37

Citadel Advisors Llc 0.25

TWO SIGMA SECURITIES, LLC 0.24

Morgan Stanley - Brokerage Accounts 0.17

Jane Street Group LLC 0.17

BNP Paribas Arbitrage, SA 0.16

P & S Renditefonds T 0.11

UBS Group AG 0.08

Fidelity Nasdaq Composite Index 0.05

Bank of America Corp 0.03

SBI Securities Co Ltd 0.01

Steward Partners Investment Advisory, LLC 0.01

Federation des caisses Desjardins du Quebec 0.01

Tradewinds Capital Management, LLC 0.00

Advisor Group Holdings, Inc. 0.00

Royal Bank of Canada 0.00

U.S. Bancorp 0.00

Armistice Capital, LLC 0.00

JPMorgan Chase & Co 0.00

Synergy Financial Management, LLC 0.00

Tidemark LLC 0.00

XTX Topco Ltd 0.00

Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 9.61 M

PB Ratio 7.8616

PE Ratio 0.0

Enterprise Value -4.08 M

Total Assets 39.86 M

Volume 52086

Company Financials

Annual Revenue FY23:5722000 5.7M, FY22:1675000 1.7M, FY21:930000 0.9M, FY20:1040000 1.0M, FY19:753000 0.8M

Annual Profit FY23:4064000 4.1M, FY22:766000 0.8M, FY21:163000 0.2M, FY20:466000 0.5M, FY19:419000 0.4M

Annual Net worth FY23:-20276000 -20.3M, FY22:-29844000 -29.8M, FY21:-30445000 -30.4M, FY20:-26206000 -26.2M, FY19:-19115000 -19.1M

Quarterly Revenue Q3/2025:312000 0.3M, Q2/2025:884000 0.9M, Q1/2025:2444000 2.4M, Q3/2024:1796000 1.8M, Q2/2024:914000 0.9M

Quarterly Profit Q3/2025:-126000 -0.1M, Q2/2025:458000 0.5M, Q1/2025:251000 0.3M, Q3/2024:715000 0.7M, Q2/2024:-236000 -0.2M

Quarterly Net worth Q3/2025:3874000 3.9M, Q2/2025:-4462000 -4.5M, Q1/2025:-2587000 -2.6M, Q3/2024:-7630000 -7.6M, Q2/2024:-5419000 -5.4M

Fund house & investment objective

Company Information Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.

Organisation Biotechnology

Employees 117

Industry Biotechnology

CEO Mr. Ofer Haviv CPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow